To include your compound in the COVID-19 Resource Center, submit it here.

European beachhead

Epirus thinks reverse merger with Zalicus will open up Europe for biosimilars

European beachhead

Epirus Biopharmaceuticals Inc. hopes its $36 million series B round and reverse merger with Zalicus Inc. (NASDAQ:ZLCS) will enable the biosimilars company to crack the European market.

The combined public company will retain Epirus' name and focus on

Read the full 380 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE